Additionally, both SR141716A and TXX-522 dramatically decreased the fasting blood glucose and insulin levels, but oral glucose tolerance testing showed that TXX-522 (5 mg/kg) ameliorated glucose intolerance more than the same dose of SR141716A did (Figures 7D,E). This evidence concerns the gene INS and Glucose intolerance.